Neuropathic Pain | Access and Reimbursement | US | 2018

Neuropathic pain (NP) is a heterogeneous disorder arising from a wide variety of diseases and conditions, and as a result, patient response to drug therapy is often unpredictable. Despite the need for new products in this space, such therapies will struggle to clinically differentiate themselves from current therapies, and a growing generic presence across multiple drug classes will result in increasing market access challenges for branded therapies. In this Access & Reimbursement analysis, how market access barriers shape treatment for NP in the United States is explored, based on collective insight from 100 physicians and 30 MCO PDs/MDs with influence in reimbursement and access of key agents used to treat NP.

Questions Answered

• What are the current drivers and barriers to prescribing NP therapies in the United States, and how do cost and reimbursement pressures or clinical concerns restrict prescribing of current treatments for NP?
• What formulary coverage do key NP therapies receive, and what approaches do payers employ to manage utilization and costs?
• How are MCO PDs/MDs performing value assessments for therapies, and what are the preferred pharmacoeconomic models?
• What will be the impact of Pfizer’s pregabalin CR on NP reimbursement dynamics, and how will the emergence of future generic pregabalin formulations impact formulary and prescribing decisions?
• How will emerging therapies (e.g., Biogen’s BIIB-074) be reimbursed and prescribed in an increasingly genericized NP market?

Product Description

Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Markets covered: United States

Primary research:

• Survey of 50 PCPs, 25 pain specialists, and 25 neurologists in the United States.
• Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).

Key companies: Acorda Therapeutics, Biogen, Depomed, Janssen, NeurogesX, Pfizer, Purdue Pharma, Validus Pharmaceuticals,  XenoPort

Key drugs: Lyrica/Lyrica CR, Gralise, Horizant, Equetro, Nucynta ER, OxyContin, Qutenza, vixotrigine (BIIB-074)

Content highlights:

• Reimbursement and contracting.
• Access and prescribing.
• Special topics.
• Opportunities and challenges for emerging therapies.